ACADIA Pharmaceuticals Inc Resubmission of sNDA for Pimavanserin for the Treatment of ADP Call Transcript - Thomson StreetEvents

ACADIA Pharmaceuticals Inc Resubmission of sNDA for Pimavanserin for the Treatment of ADP Call Transcript

ACADIA Pharmaceuticals Inc Resubmission of sNDA for Pimavanserin for the Treatment of ADP Call Transcript - Thomson StreetEvents
ACADIA Pharmaceuticals Inc Resubmission of sNDA for Pimavanserin for the Treatment of ADP Call Transcript
Published Dec 20, 2021
14 pages (8128 words) — Published Dec 20, 2021
Price US$ 54.00  |  Buy this Report Now

About This Report

  
Abstract:

Edited Transcript of ACAD.OQ conference call or presentation 20-Dec-21 9:30pm GMT

  
Brief Excerpt:

...Operator Good day, ladies and gentlemen, and welcome to the ACADIA Pharmaceuticals conference call. My name is Latif, and I will be your coordinator for today. (Operator Instructions) I would now like to turn the presentation over to Mark Johnson, Vice President of Investor Relations at ACADIA. Please proceed. Mark C. Johnson ...

  
Report Type:

Transcript

Source:
Thomson StreetEvents
Company:
ACADIA Pharmaceuticals Inc
Ticker
ACAD.OQ
Time
9:30pm GMT
Format:
PDF Adobe Acrobat
Buy Now

The following is excerpted from the question-and-answer section of the transcript.

(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)

Question: Gavin Scott - JPMorgan Chase & Co, Research Division - Analyst : This is Gavin on for Cory. I'm just curious on the level of input and/or feedback from FDA that gives you confidence in this resubmission strategy. I mean, did they suggest they would convene an AdComm? Or was there any discussion on that as part of this filing strategy?

Question: Sumant Satchidanand Kulkarni - Canaccord Genuity Corp., Research Division - Analyst : Given the FDA has restated advice that an additional study in ADP is the best way forward, is it fair to assume that you currently have a high degree of confidence that the FDA will specifically accept your sNDA for filing? I guess just any thoughts on that I'll appreciate.

Question: Gregory James Renza - RBC Capital Markets, Research Division - Analyst : Maybe Steve, just building on the previous ones already asked. How difficult of a decision was this for you to pursue the resubmission now, certainly in light of the confidence that you've reiterated, but also the FDA stance on the additional trial and especially just given that this entails really establishing and deploying your resources and energy to this effort now? And maybe just building on that, if there's any spend color or change to use of cash that you could allude to, that would be great?

Table Of Contents

ACADIA Pharmaceuticals Inc Q1 2022 Earnings Call Transcript – 2022-05-04 – US$ 54.00 – Edited Transcript of ACAD.OQ earnings conference call or presentation 4-May-22 8:30pm GMT

ACADIA Pharmaceuticals Inc at Needham Neuroscience Forum (Virtual) Transcript – 2022-03-16 – US$ 54.00 – Edited Transcript of ACAD.OQ presentation 16-Mar-22 7:20pm GMT

ACADIA Pharmaceuticals Inc at Cowen Health Care Conference (Virtual) Transcript – 2022-03-09 – US$ 54.00 – Edited Transcript of ACAD.OQ presentation 9-Mar-22 7:50pm GMT

ACADIA Pharmaceuticals Inc Q4 2021 Earnings Call Transcript – 2022-02-28 – US$ 54.00 – Edited Transcript of ACAD.OQ earnings conference call or presentation 28-Feb-22 9:30pm GMT

ACADIA Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript – 2022-01-11 – US$ 54.00 – Edited Transcript of ACAD.OQ presentation 11-Jan-22 3:30pm GMT

ACADIA Pharmaceuticals Inc Announces Positive Top-line Results Call Transcript – 2021-12-06 – US$ 54.00 – Edited Transcript of ACAD.OQ conference call or presentation 6-Dec-21 9:30pm GMT

ACADIA Pharmaceuticals Inc Q3 2021 Earnings Call Transcript – 2021-11-08 – US$ 54.00 – Edited Transcript of ACAD.OQ earnings conference call or presentation 8-Nov-21 9:30pm GMT

ACADIA Pharmaceuticals Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript – 2021-09-13 – US$ 54.00 – Edited Transcript of ACAD.OQ presentation 13-Sep-21 3:45pm GMT

ACADIA Pharmaceuticals Inc at Citi BioPharma Conference (Virtual) Transcript – 2021-09-10 – US$ 54.00 – Edited Transcript of ACAD.OQ presentation 10-Sep-21 3:35pm GMT

ACADIA Pharmaceuticals Inc Q2 2021 Earnings Call Transcript – 2021-08-04 – US$ 54.00 – Edited Transcript of ACAD.OQ earnings conference call or presentation 4-Aug-21 8:30pm GMT

More from Thomson StreetEvents

Thomson StreetEvents—Thomson StreetEvents is a leading provider of Web-based solutions for the investment community, offering services that transform the way companies communicate and meet disclosure requirements while assisting investors in managing and leveraging this information. Thomson StreetEvents service offers institutional investors a one-stop solution for managing corporate disclosure information by aggregating conference calls, webcasts, transcripts, call summaries, and other financial information into a time-saving, efficiency tool.
Purchase Thomson StreetEvents' Transcripts (verbatim reports) and Briefs (call summaries) of earnings, guidance, M&A and other corporate calls directly through Alacra. Discounted prices apply to reports produced over two weeks ago.

About the Author


Cite this Report

  
MLA:
Thomson StreetEvents. "ACADIA Pharmaceuticals Inc Resubmission of sNDA for Pimavanserin for the Treatment of ADP Call Transcript" Dec 20, 2021. Alacra Store. May 12, 2025. <http://www.alacrastore.com/thomson-streetevents-transcripts/ACADIA-Pharmaceuticals-Inc-Resubmission-of-sNDA-for-Pimavanserin-for-the-Treatment-of-ADP-Call-T15078386>
  
APA:
Thomson StreetEvents. (2021). ACADIA Pharmaceuticals Inc Resubmission of sNDA for Pimavanserin for the Treatment of ADP Call Transcript Dec 20, 2021. New York, NY: Alacra Store. Retrieved May 12, 2025 from <http://www.alacrastore.com/thomson-streetevents-transcripts/ACADIA-Pharmaceuticals-Inc-Resubmission-of-sNDA-for-Pimavanserin-for-the-Treatment-of-ADP-Call-T15078386>
  
US$ 54.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Credit Research from one place.